Daiichi Sankyo Executive and Leadership Team

Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, manages the strategic priorities and daily operations of the executive office. Overseeing the implementation of corporate vision, the Chief of Staff To Chief Executive Officer facilitates communication between the board and senior leadership teams. This leadership role involves synthesizing complex business data to support high-level decision-making regarding global pharmaceutical expansion. By aligning departmental goals with the overarching mission, Kazuki Mori directly impacts the agility of the organization in responding to market shifts. The Chief of Staff To Chief Executive Officer coordinates cross-functional projects that drive innovation in drug development and delivery. Through rigorous management of executive workflows, the Chief of Staff To Chief Executive Officer ensures that strategic initiatives receive the necessary focus and resources. Ultimately, Mori enables the Chief Executive Officer to maintain a clear focus on long-term growth and the delivery of high-quality medicines to patients.

Hiroyuki Okuzawa, the Chief Financial Officer at Daiichi Sankyo, directs the global financial strategy and capital allocation processes. Overseeing fiscal health, the Chief Financial Officer manages complex budgetary frameworks to support advanced drug discovery initiatives. This leadership role involves coordinating with international stakeholders to ensure sustainable growth across the pharmaceutical portfolio. By optimizing resource distribution, Hiroyuki Okuzawa directly impacts the ability of the organization to fund research and development in over 30 countries. The Chief Financial Officer maintains rigorous oversight of financial reporting standards, ensuring transparency and long-term stability for shareholders. Through precise fiscal management, the Chief Financial Officer secures the necessary capital to drive innovation in medicine delivery methods. Ultimately, Okuzawa strengthens the financial foundation required to sustain the competitive market position of the company while navigating the evolving regulatory landscape of the global pharmaceutical industry.

Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, executes financial forecasting and long-term planning initiatives to support the pharmaceutical business model. Overseeing the development of budgetary models, the Manager, Chief Financial Officer Planning Department ensures that financial resources align with research and development priorities. This leadership role involves analyzing market trends to provide actionable insights for the executive team. By refining financial planning processes, Chloe Stern directly impacts the accuracy of corporate projections and investment strategies. The Manager, Chief Financial Officer Planning Department collaborates with various departments to monitor performance metrics and identify opportunities for cost optimization. Through detailed financial analysis, the Manager, Chief Financial Officer Planning Department supports the strategic goals of the company in over 30 countries. Ultimately, Stern provides the analytical rigor necessary for the organization to maintain financial health while pursuing advancements in drug discovery and delivery.

Suthas Thongprasert, the President at Daiichi Sankyo, directs the overall operational strategy and market expansion efforts for the pharmaceutical organization. Overseeing the execution of corporate objectives, the President ensures that the company maintains its commitment to providing innovative medicines to patients across diverse regions. This leadership role involves managing the performance of regional operations to drive sustainable revenue growth. By fostering a culture of excellence, Suthas Thongprasert directly impacts the ability of the company to deliver advanced drug discovery solutions. The President coordinates with the board and senior leadership to define the long-term vision for the pharmaceutical portfolio. Through strategic oversight of market presence, the President drives initiatives that enhance the competitive standing of the company in the global healthcare sector. Ultimately, Thongprasert ensures that the organization remains focused on its mission to improve patient outcomes through scientific innovation and operational efficiency.

Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, coordinates strategic initiatives within the oncology division to accelerate the delivery of innovative cancer treatments. Overseeing cross-functional collaboration, the Global Oncology Medical Affairs Chief of Staff ensures alignment between clinical research and medical communication strategies. This leadership role involves managing complex workflows to support the global launch of new therapeutic agents. By streamlining internal processes, Caitlin Barnabo directly impacts the efficiency of medical affairs operations across diverse international markets. The Global Oncology Medical Affairs Chief of Staff facilitates communication between scientific teams and executive leadership to prioritize patient outcomes. Through meticulous project management, the Global Oncology Medical Affairs Chief of Staff drives the execution of medical education programs that define the clinical value of the oncology portfolio. Ultimately, Barnabo ensures the successful integration of scientific data into the broader commercial strategy of the company.

Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, architects the digital infrastructure and operational systems that support global pharmaceutical manufacturing. Overseeing the integration of advanced technology, the Chief of Staff & Global System Owner ensures seamless data flow across international research and production facilities. This leadership role involves managing the lifecycle of critical enterprise systems to maintain operational excellence. By optimizing system performance, Kosuke Itagaki directly impacts the efficiency of drug discovery and delivery processes. The Chief of Staff & Global System Owner coordinates with technical teams to implement scalable solutions that meet the rigorous demands of the global pharmaceutical market. Through strategic oversight of system architecture, the Chief of Staff & Global System Owner drives digital transformation initiatives that enhance productivity. Ultimately, Itagaki secures the technological backbone necessary for the company to maintain its leadership in providing innovative medicines to patients worldwide.